The Anemia Market: Biogenerics and Second-Generation Products Drive Change

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Causes of Anemia
• Treatment Options
• Current Market
  • United States
  • Europe
  • Japan
• Emerging Therapies
  • New Biologics
    • Roche/Chugai' s Mircera
    • Affymax/Takeda' s Hematide
    • Neose' s NE-180
  • Small-Molecule Therapeutics
    • Fibrogen/Astellas' s FG-2216
    • ProMetic' s PBI-1402
• Biogenerics
  • Regulatory Hurdles to Biogenerics
  • Pricing
  • Biogeneric EPO Products
• Market Outlook
  • United States
  • Europe
  • Japan
  • Emergence of New Market Leaders

Tables:

• 1. Sales of Erythropoietin Products, 2005
• 2. Products in Clinical Development for the Treatment of Anemia
• 3. Biogeneric Erythropoietin Products in Development for the Treatment of Anemia- Europe

Figures:

• 1. Erythropoiesis
• 2. Market Share of Key Players in the Anemia Market, 2005
• 3. U.S. Sales of Recombinant Erythropoietin Products, 2000-2005